Physician profile
Brandy Jo Smith
NPI 1558878702
$6,864.89
in general payments reported to CMS, 2019-2025
29 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,239 · 2022: $1,479 · 2023: $1,340 · 2024: $1,566 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,611 · Travel and Lodging: $378 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,611.10 |
| Travel and Lodging | $377.83 |
| Education | $158.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,011.69 | 2021-2025 | |
| Janssen Biotech, INC. | $661.99 | 2021-2025 | Tremfya |
| Amgen INC. | $612.53 | 2021-2025 | Otezla, Otezla |
| Merz North America, INC. | $496.95 | 2024 | |
| Incyte Corporation | $487.01 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $442.31 | 2023-2025 | Sotyktu |
| Abbvie INC. | $427.00 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $423.74 | 2021-2024 | Ilumya |
| Genzyme Corporation | $422.47 | 2021-2024 | |
| Ucb, INC. | $371.64 | 2022-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $274.00 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $230.01 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Allergan, INC. | $189.72 | 2022 | |
| Dermavant Sciences, INC. | $122.55 | 2023 | Vtama |
| Janssen Scientific Affairs, LLC | $120.86 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $94.36 | 2023-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $85.39 | 2025 | |
| Biofrontera INC. | $70.85 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.26 | 2021-2024 | Cabtreo |
| Pfizer INC. | $50.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.58 | 2023-2024 | Spevigo, Cyltezo |
| Leo Pharma INC. | $42.24 | 2022 | |
| Organogenesis INC. | $23.10 | 2024 | |
| Stemline Therapeutics INC. | $19.41 | 2022 | |
| Lnhc, INC | $18.07 | 2025 | Zelsuvmi |
| Celgene Corporation | $17.41 | 2024 | Sotyktu |
| Tactile Systems Technology INC | $14.67 | 2022 | |
| Convatec INC. | $14.07 | 2024 | |
| Mayne Pharma Commercial LLC | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.